---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-095926"
form_type: "8-K"
ticker: "NEUP"
cik: "0001191070"
company_name: "Neuphoria Therapeutics Inc."
filed_at: "2024-11-08T23:59:59+00:00"
generated_at: "2026-05-30T02:42:51.382407+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Bionomics announces amended exchange ratio for re-domicile merger; court approves Dec 12 meeting

## Summary
- Amended exchange ratio: 1 Neuphoria share per 2,160 Bionomics ordinary shares; 1 per 12 ADSs.
- Supreme Court of New South Wales approved convening of shareholder meeting on Dec 12, 2024.
- Bionomics has Nasdaq minimum bid price deficiency notice; expects compliance after scheme completion.
- Re-domicile from Australia to Delaware; Neuphoria common stock to list on Nasdaq.

## SEC filing metadata
- accession: 0001213900-24-095926
- form_type: 8-K
- ticker: NEUP
- cik: 0001191070
- company_name: Neuphoria Therapeutics Inc.
- filed_at: 2024-11-08T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1191070/000121390024095926/0001213900-24-095926-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1191070/000121390024095926/ea0218750-8k_bionomics.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-095926
- JSON: https://secwatch.observer/filing/0001213900-24-095926.json
- Plain text: https://secwatch.observer/filing/0001213900-24-095926.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.